Cart
Albumin Market by Product (Human Serum Albumin, Bovine Serum Albumin, and Recombinant Albumin) and Application (Therapeutics, Drug Formulation & Vaccine, Component of Media, and Other Applications) - Global Opportunity Analysis and Industry Forecast, 2016-2023
|
LI_182583
|
Pages: 185
|
May
2018 |
3521 Views
|
|
|
|
Author(s) :
Pallavi Jaiswal & Mayuri Srivastava
|
Tables: 89
|
Charts: 41
|
Formats*:
|
|
Albumin Market Overview:
The Global Albumin Market was valued at $5,381 million in 2016, and is projected to reach $10,305 million at a CAGR of 9.6% from 2017 to 2023. Albumin is the most abundant protein found in blood plasma. It serves a wide range of functions such as transporting hormones and fatty acids and maintains oncotic pressure. Therapeutically, it is used to replace lost fluid and helps restore blood volume due to trauma, burns, surgeries, or infections and liver diseases. It assists in the stabilization of drugs by reducing aggregation, oxidation, and surface absorption. Different types of serum albumin are widely used for clinical applications. Human serum albumin and bovine serum albumin are obtained from human plasma and bovine plasma, respectively. On the other hand, recombinant albumin is manufactured by recombinant techniques in yeast and bacteria strains.
Get more information on this report : Request Sample Pages
Market Dynamics
Increase in prevalence of life-threatening disorders and conditions, especially liver diseases, infections, and cardiac surgeries leading to hypoalbuminemia. Other factors that boost the market growth include rise in adoption of albumin products, upsurge in albumin products usage for non-therapeutic application across the world, and increase in awareness recombinant albumin. However, factors such as stringent governmental regulations and post-operative risks associated with albumin-based therapy hamper the market growth. Conversely, the development of cost-effective therapeutics along with large scale production of albumin and high potential in untapped markets in the emerging economies are expected to provide lucrative growth opportunities for the market.
Market Segmentation
The global albumin market is segmented into product, application, and region. Based on product, the market is divided into human serum albumin, bovine serum albumin, and recombinant albumin. Human serum albumin segment accounted for the largest market share in 2016, and is expected to continue this trend throughout the forecast period owing to high production of human serum albumin and it has widespread application in therapeutics as blood volumizer. On the other hand, recombinant albumin segment is anticipated to grow at a significant CAGR of 11.4% during the forecast period. This is due to rise in awareness about recombinant albumin and utilization of recombinant albumin in drug and vaccine formulations.
Get more information on this report : Request Sample Pages
By application, the market is categorized into therapeutics, drug formulation & vaccine, component of media, and other applications. Therapeutics segment accounted for the largest market share in 2016 due to increase in prevalence of trauma, burns cases, and rise in number of surgical procedures. Whereas, drug formulation & vaccines segment is expected to register the highest growth rate during the forecast period.
Get more information on this report : Request Sample Pages
Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share of the market in 2016, followed by Europe. On the other hand, Asia-Pacific is anticipated to dominate the market during the analysis period, owing to high population base, increase in disposable income, and improvement in patient awareness about albumin products. Moreover, Asia is a large continent, and thus has emerged as an epicenter of life-threatening diseases.
Get more information on this report : Request Sample Pages
The key players of this market include Grifols S.A., Octapharma AG, China Biologic Products Inc., Shire Plc, Ventria Bioscience, CSL Limited, Albumedix Ltd., Merck KGaA, Thermo Fisher Scientific, and Baxter International Inc.
Other players (these players are not profiled in the report and the same can be included on request) in the value chain include Biotest AG, Medxbio Pte Ltd., Mitsubishi Tanabe Pharma Corporation, Kedrion S.p.A, HiMedia Leading BioSciences Company, and Celgene Corporation.
Key Benefits
- The study provides an in-depth analysis of the global albumin market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Albumin Market Key Segments:
By Product
- Human Serum Albumin
- Bovine Serum Albumin
- Recombinant Albumin
By Application
- Therapeutics
- Drug Formulation & Vaccine
- Component of Media
- Other Applications
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Market share analysis, 2016
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of rare diseases and various life-threatening conditions
3.4.1.2. Increase in demand for albumin
3.4.1.3. Growing preferences for recombinant albumin
3.4.1.4. Rise in non-therapeutic application of albumin
3.4.2. Restraints
3.4.2.1. Stringent government regulations
3.4.2.2. Risks associated with albumin
3.4.3. Opportunities
3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of cost effective therapeutics through large scale production
3.4.4. Impact analyses
3.5. Government regulations
3.6. Patent analysis (2013-2018)
3.6.1. Patent analysis, by year
3.6.2. Patent analysis for year 2017, by country
CHAPTER 4: ALBUMIN MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Human serum albumin
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Bovine serum albumin
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Recombinant albumin
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: ALBUMIN MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast (value)
5.2. Therapeutics
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Drug formulation & vaccines
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Component of media
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Other applications
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
CHAPTER 6: ALBUMIN MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America albumin market, by country
6.2.2.1. U.S.
6.2.2.1.1. Market size and forecast, by product
6.2.2.1.2. Market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Market size and forecast, by product
6.2.2.2.2. Market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Market size and forecast, by product
6.2.2.3.2. Market size and forecast, by application
6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Market size and forecast, by product
6.3.2.1.2. Market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. Market size and forecast, by product
6.3.2.2.2. Market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. Market size and forecast, by product
6.3.2.3.2. Market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Market size and forecast, by product
6.3.2.4.2. Market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Market size and forecast, by product
6.3.2.5.2. Market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Market size and forecast, by product
6.3.2.6.2. Market size and forecast, by application
6.3.2.6.3. Europe market size and forecast, by product
6.3.2.6.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Market size and forecast, by product
6.4.2.1.2. Market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. Market size and forecast, by product
6.4.2.2.2. Market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. Market size and forecast, by product
6.4.2.3.2. Market size and forecast, by application
6.4.2.4. Australia
6.4.2.4.1. Market size and forecast, by product
6.4.2.4.2. Market size and forecast, by application
6.4.2.5. South Korea
6.4.2.5.1. Market size and forecast, by product
6.4.2.5.2. Market size and forecast, by application
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Market size and forecast, by product
6.4.2.6.2. Market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Market size and forecast, by product
6.5.2.1.2. Market size and forecast, by application
6.5.2.2. Saudi Arabia
6.5.2.2.1. Market size and forecast, by product
6.5.2.2.2. Market size and forecast, by application
6.5.2.3. South Africa
6.5.2.3.1. Market size and forecast, by type
6.5.2.3.2. Market size and forecast, by application
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Market size and forecast, by product
6.5.2.4.2. Market size and forecast, by application
6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Baxter International Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. China Biologic Products Holdings, Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. CSL Limited
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Grifols S.A. (Grifols International, S.A.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Merck KGaA
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Novozymes A/S (Albumedix Ltd.)
7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance
7.7. Octapharma AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Shire Plc. (Shire US, Inc.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Thermo Fisher Scientific Inc (Affymetrix, Inc.)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Ventria Bioscience
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Product portfolio
LIST OF TABLES
TABLE 01. MARKETED FORMULATION OF ALBUMIN
TABLE 02. GLOBAL ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 03. HUMAN SERUM ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. BOVINE SERUM ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. RECOMBINANT ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. GLOBAL ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 07. ALBUMIN MARKET FOR THERAPEUTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 08. ALBUMIN MARKET FOR DRUG FORMULATION & VACCINES, BY REGION, 2016-2023 ($MILLION)
TABLE 09. ALBUMIN MARKET FOR COMPONENT OF MEDIA, BY REGION, 2016-2023 ($MILLION)
TABLE 10. ALBUMIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. NORTH AMERICA ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13. U.S. ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 14. U.S. ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 15. CANADA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 16. CANADA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17. MEXICO ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 18. MEXICO ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 21. EUROPE ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 22. GERMANY ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 23. GERMANY ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 24. FRANCE ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 25. FRANCE ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 26. UK ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 27. UK ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. ITALY ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 29. ITALY ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. SPAIN ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 31. SPAIN ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. REST OF EUROPE ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 33. REST OF EUROPE ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. EUROPE ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 35. EUROPE ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. ASIA-PACIFIC ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. JAPAN ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 38. JAPAN ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. CHINA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 40. CHINA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. INDIA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 42. INDIA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. AUSTRALIA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 44. AUSTRALIA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. SOUTH KOREA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 46. SOUTH KOREA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. ASIA-PACIFIC ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 50. ASIA-PACIFIC ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. LAMEA ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 52. BRAZIL ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 53. BRAZIL ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 54. SAUDI ARABIA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 55. SAUDI ARABIA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 56. SOUTH AFRICA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 57. SOUTH AFRICA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 58. REST OF LAMEA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 59. REST OF LAMEA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. LAMEA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 61. LAMEA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 62. BAXTER: COMPANY SNAPSHOT
TABLE 63. BAXTER: OPERATING SEGMENTS
TABLE 64. BAXTER: PRODUCT PORTFOLIO
TABLE 65. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 66. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 67. CSL: COMPANY SNAPSHOT
TABLE 68. CSL: PRODUCT SEGMENTS
TABLE 69. CSL: PRODUCT PORTFOLIO
TABLE 70. GRIFOLS: COMPANY SNAPSHOT
TABLE 71. GRIFOLS: OPERATING SEGMENTS
TABLE 72. GRIFOLS: PRODUCT PORTFOLIO
TABLE 73. MERCK: COMPANY SNAPSHOT
TABLE 74. MERCK: PRODUCT SEGMENTS
TABLE 75. MERCK: PRODUCT PORTFOLIO
TABLE 76. NOVOZYMES A/S: COMPANY SNAPSHOT
TABLE 77. NOVOZYMES A/S: PRODUCT CATEGORIES
TABLE 78. NOVOZYMES A/S: PRODUCT PORTFOLIO
TABLE 79. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 80. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 81. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 82. SHIRE: COMPANY SNAPSHOT
TABLE 83. SHIRE: PRODUCT PORTFOLIO
TABLE 84. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 85. THERMO FISHER SCIENTIFIC INC: OPERATING SEGMENTS
TABLE 86. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 87. VENTRIA: COMPANY SNAPSHOT
TABLE 88. VENTRIA: PRODUCT CATEGORIES
TABLE 89. VENTRIA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ALBUMIN MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2016
FIGURE 04. AGE DISTRIBUTION OF BURN PATIENTS BY GENDER IN INDIA, 2013 (IN PERCENTAGE)
FIGURE 05. IMPACT ANALYSES
FIGURE 06. PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2018
FIGURE 07. PATENTS ANALYSIS BY YEAR, 2013 THROUGH 2018
FIGURE 08. YEAR 2017 PATENT ANALYSIS, BY COUNTRY
FIGURE 09. COMPARATIVE ANALYSIS OF HUMAN SERUM MARKET, 2016-2023 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF BOVINE SERUM ALBUMIN MARKET, 2016-2023 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF RECOMBINANT ALBUMIN MARKET, 2016 & 2023 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR THERAPEUTICS, 2016-2023 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR DRUG FORMULATION & VACCINES,
2016 & 2023 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR COMPONENT OF MEDIA, 2016 & 2023 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR OTHER APPLICATIONS, 2016 & 2023 ($MILLION)
FIGURE 16. NUMBER OF CARDIOVASCULAR SURGERIES IN CANADA FROM 2007 TO 2014
FIGURE 17. INCIDENCE RATE OF DIFFERENT TYPES CANCER IN GERMANY 2012
FIGURE 18. NUMBER OF ORGANS TRANSPLANTED IN CHINA FROM 2010 TO 2015
FIGURE 19. BAXTER: NET SALES, 2015-2017 ($MILLION)
FIGURE 20. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 21. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: REVENUE, 2015-2017 ($MILLION)
FIGURE 23. CSL: NET SALES, 2015-2017 ($MILLION)
FIGURE 24. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. GRIFOLS: REVENUE, 2015-2017 ($MILLION)
FIGURE 27. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. GRIFOLS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 30. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. NOVOZYMES A/S: REVENUE, 2015-2017 ($MILLION)
FIGURE 33. NOVOZYMES A/S: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. NOVOZYMES A/S: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 35. OCTAPHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 36. SHIRE: NET SALES, 2015-2017 ($MILLION)
FIGURE 37. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 38. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. THERMO FISHER SCIENTIFIC INC: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. THERMO FISHER SCIENTIFIC INC: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. THERMO FISHER SCIENTIFIC INC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Albumin is the most abundant plasma protein, constituting approximately 50% of total plasma protein. It is produced in the liver and maintains oncotic pressure of blood, and transports hormones, fatty acids, and other compounds. It is obtained from human and animal’s plasma by fractionation that is further used to treat different disorders.
Rise in number of patients suffering from life-threatening diseases and conditions, especially hypoalbuminemia, is the major factor that drives the growth of the global albumin market. Other factors such as increase in demand for albumin products, rise in non-therapeutic application of albumin, and surge in preferences for recombinant albumin products usage in various treatments are expected to have a significant impact on the growth of the market. However, factors such as stringent governmental regulations and post-operative risks associated with donated albumin hamper the market growth.
The use of albumin is the highest in North America, owing to the presence of large patient population and high adoption of recombinant albumin, followed by Europe and Asia-Pacific. In addition, albumin providers and distributors have focused on expanding their presence in the emerging economies, which in turn is anticipated to drive the market growth.
Download Sample
Purchase Full Report of
Albumin Market- Global Opportunity Analysis and Industry Forecast, 2016-2023
- Online Only
- $3456
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3840
- Restricted to one authorized user
- One print only
- Available in Excel
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5370
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6450
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8995
- Unlimited within company/enterprise
- Available in Excel & PDF
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Buy Full Version
"Albumin Market"
Purchase Enquiry